Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532

In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Vol. 28; no. 1; pp. 63 - 68
Main Authors: Perry, Michael C, Ihde, Daniel C, Herndon II, James E, Grossbard, Michael L, Grethein, Sara J, Atkins, James N, Vokes, Everett E, Green, Mark R
Format: Journal Article
Language:English
Published: Shannon Elsevier Ireland Ltd 01-04-2000
Elsevier Science
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a ‘proof of principle’ that non-cisplatin containing regimens also have activity in this setting.
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(99)00129-4